Find disease awareness content and relevant supporting materials

The FDA approved Elzonris (tagraxofusp-erzs) infusion from Stemline Therapeutics, for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in...

This addendum updates the 2009 Canadian psoriasis guidelines with new insights into T-cell involvement, particularly the role of Th17 and IL-17-producing dermal γδT cells. It outlines the evolving understanding of immune pathways driving keratinocyte hyperproliferation and inflammation in plaque psoriasis.

The Menarini Group announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion on the approval of Elzonris (tagraxofusp) as monotherapy for the first-line treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), an aggressive hematologic malignancy with dismal outcomes.

The Menarini Group announced that the European Commission (EC) has granted a marketing authorization, for Elzonris (tagraxofusp) as monotherapy for the first-line treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare, aggressive hematologic malignancy with dismal outcomes.

Stemline Therapeutics, Inc.announced an agreement with the FDA on the registration pathway for SL 401 in blastic plasmacytoid dendritic cell...

In this review, we discuss the roles of IL-17A, IL-17F and IL-17C in psoriasis and HS and the strategies taken to target the IL-17 pathway therapeutically.

The major cell types and inflammatory pathways in skin of patients with HS are poorly understood, and which patients will respond to TNF-α blockade is currently unknown.

Stemline Therapeutics, Inc. , a biopharmaceutical company focused on the development and potential commercialization of novel oncology therapeutics, announced that...

Stemline Therapeutics announced that it has completed submission of a rolling Biologics License Application (BLA) to the FDA for Elzonris...

Asthma is characterised by chronic airway inflammation, airway obstruction and hyper-responsiveness. The inflammatory cascade in asthma comprises a complex interplay of genetic factors, the airway epithelium, and dysregulation...